Literature DB >> 3882270

Effects of nifedipine on systemic and regional oxygen transport and metabolism at rest and during exercise.

C Y Choong, G S Roubin, W F Shen, P J Harris, D T Kelly.   

Abstract

In a placebo-controlled, randomized, cross-over, double-blind study of 12 patients with stable exertional angina, we measured at rest and during bicycle exercise the effects of 20 mg of nifedipine administered sublingually on hemodynamics and systemic and regional oxygen extraction and metabolism. Nifedipine decreased systemic vascular resistance by 38% at rest (p less than .001) and by 28% during exercise (p less than .001). Cardiac output increased from 4.6 +/- 0.6 to 6.0 +/- 0.9 liters/min (p less than .001) at rest after nifedipine and from 10.6 +/- 3.7 to 11.8 +/- 3.4 liters/min (p less than .005) during exercise. After nifedipine, the arterial-mixed venous O2 content difference decreased from 4.7 +/- 0.6 to 3.5 +/- 0.5 ml/100 ml (p less than .001) at rest and from 10.5 +/- 1.7 to 8.8 +/- 1.6 ml/100 ml (p less than .001) during exercise. After nifedipine the arterial-iliac venous O2 content difference also decreased at rest, from 5.9 +/- 1.5 to 4.8 +/- 1.7 ml/100 ml (p = .06) but increased during exercise from 13.1 +/- 1.5 to 14.0 +/- 1.8 ml/100 ml (p less than .05). Oxygen consumption was not significantly altered at rest or during exercise. Nifedipine decreased mixed venous carbon dioxide tension (PCO2) during exercise from 53 +/- 3.5 to 50 +/- 4.0 mm Hg (p less than .05) but increased iliac venous PCO2 slightly from 61 +/- 4.6 to 63 +/- 5.2 mm Hg (p less than .01). Exercise pH was not significantly altered, but arterial lactate increased more after nifedipine (2.65 +/- 1.95 mmol/liter placebo, 3.54 +/- 2.74 mmol/liter nifedipine; p less than .05). Thus nifedipine produces similar changes in O2 extraction in mixed venous and iliac venous blood at rest but directionally opposite changes during exercise. The data support the hypothesis that nifedipine does not alter the distribution of cardiac output to the legs at rest, but during dynamic leg exercise reduces the redistribution of cardiac output to the legs. This probably results from the shunting of blood flow away from exercising muscles by the generalized vasodilatation of nifedipine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882270     DOI: 10.1161/01.cir.71.4.787

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Pharmacodynamics of salmon calcitonin in humans: new markers of pharmacological activity.

Authors:  T Di Perri; F Laghi Pasini; P L Capecchi; P Blardi; A L Pasqui; M Franchi; S Mazza; N Sodi; L Domini; L Ceccatelli
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Effects of atenolol, slow-release nifedipine, and their combination on respiratory gas exchange and exercise tolerance in stable effort angina.

Authors:  S Wieshammer; M Hetzel; U Barnikel; M Höher; H Seibold; M Kochs; V Hombach
Journal:  Klin Wochenschr       Date:  1991-09-16

3.  Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects.

Authors:  K Handa; T Mori; H Tanaka; Y Takada; A Matsunaga; A Kiyonaga; M Shindo; J Sasaki; K Arakawa
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

4.  [Increase in liver circulation with nifedipine].

Authors:  J Nitsch; R Kuhnen; B Lüderitz
Journal:  Klin Wochenschr       Date:  1986-10-31

Review 5.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

6.  Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study.

Authors:  M Hori; H Sato; H Ozaki; M Inoue; M Naka; M Fukunami; M Fukushima; K Kunisada
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

7.  Verapamil in angina pectoris.

Authors:  D T Kelly
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.